Resmed (RSMDF) Non-Current Deffered Revenue (2010 - 2026)

Resmed has reported Non-Current Deffered Revenue for 17 years, with the latest figure at $163.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 7.98% year-over-year to $163.1 million; the trailing twelve-month figure through Mar 2026 stood at $163.1 million (up 7.98% YoY), and the FY2025 full-year result was $156.8 million, up 14.17% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $163.1 million, up from $159.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $163.1 million in Q1 2026, with the low at $94.1 million in Q1 2022.
• Historically, Non-Current Deffered Revenue has averaged $130.4 million across 5 years, with a median of $132.0 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue gained 4.33% — and 2023, when it rose 24.86%.
• Resmed's Non-Current Deffered Revenue stood at $102.8 million in 2022, then climbed by 23.94% to $127.4 million in 2023, then advanced by 14.99% to $146.5 million in 2024, then grew by 9.06% to $159.8 million in 2025, then climbed by 2.1% to $163.1 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $163.1 million (Q1 2026), $159.8 million (Q4 2025), and $159.4 million (Q3 2025), per Business Quant data.